Lumican Inhibitors
Lumican inhibitors form a diverse class of chemicals that exert direct or indirect modulation over the expression of Lumican, a crucial proteoglycan involved in the regulation of the extracellular matrix. Triamcinolone, functioning indirectly, inhibits Lumican expression by suppressing the TGF-β signaling pathway. By interfering with this pathway, Triamcinolone effectively downregulates Lumican, shedding light on the intricate interplay between Lumican and TGF-β signaling. In contrast, SB431542 acts as a direct Lumican inhibitor by targeting the TGF-β type I receptor (ALK5), resulting in the specific downregulation of Lumican. Galunisertib, Halofuginone, and SD-208 employ a similar strategy, directly inhibiting Lumican by targeting ALK5 and disrupting TGF-β signaling. LY2157299, Pirfenidone, and RepSox serve as inhibitors by selectively targeting ALK5, effectively suppressing TGF-β signaling and subsequently inhibiting Lumican expression.
Furthermore, LY2109761, GW788388, LY364947, and P144 offer direct inhibition by targeting ALK5 and interfering with TGF-β signaling, collectively presenting a spectrum of strategies for modulating Lumican expression. These inhibitors collectively provide valuable tools for researchers investigating Lumican's intricate role in various physiological and pathological processes. The range of approaches showcases the complexity of the regulatory network surrounding Lumican, particularly in response to TGF-β signaling cues. The nuanced interplay between these inhibitors and Lumican expression emphasizes the sophisticated regulatory mechanisms governing this proteoglycan and underscores its significance in maintaining tissue homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a potent inhibitor of the TGF-β type I receptor (ALK5), directly affecting Lumican expression. By targeting ALK5, SB431542 disrupts TGF-β signaling, resulting in the downregulation of Lumican. This compound serves as a direct inhibitor of Lumican by specifically blocking the key receptor involved in the TGF-β pathway, highlighting its potential in modulating Lumican levels in various biological contexts. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
Galunisertib (LY2157299) inhibits Lumican expression by selectively targeting the TGF-β type I receptor (ALK5). As an ATP-competitive inhibitor, Galunisertib interferes with ALK5 kinase activity, disrupting downstream TGF-β signaling and leading to the inhibition of Lumican. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
Halofuginone inhibits Lumican indirectly by disrupting the TGF-β/Smad pathway. As a prolyl-tRNA synthetase inhibitor, Halofuginone interferes with TGF-β signaling, resulting in reduced activation of Smad proteins and subsequent downregulation of Lumican. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-β RI Kinase Inhibitor V, SD-208, acts as a direct inhibitor of Lumican by targeting the TGF-β type I receptor (ALK5). By selectively inhibiting ALK5 kinase activity, SD-208 disrupts TGF-β signaling, leading to the downregulation of Lumican. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
Pirfenidone inhibits Lumican indirectly by suppressing the TGF-β signaling pathway. As an anti-fibrotic agent, Pirfenidone reduces TGF-β expression and signaling, resulting in decreased expression and activity of Lumican. This compound modulates the TGF-β pathway by inhibiting the transcriptional activation of TGF-β-responsive genes, offering an indirect approach to influence Lumican levels and function in pathological conditions associated with fibrosis. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
ALK5 Inhibitor II (RepSox) is a direct inhibitor of Lumican by targeting the TGF-β type I receptor (ALK5). By inhibiting ALK5 kinase activity, RepSox disrupts TGF-β signaling, leading to the downregulation of Lumican. This compound provides a specific means to modulate Lumican levels by directly interfering with the key receptor involved in the TGF-β pathway, highlighting its potential therapeutic applications in conditions where Lumican dysregulation contributes to pathogenesis. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 is a direct inhibitor of Lumican by targeting the TGF-β type I receptor (ALK5). By inhibiting ALK5 kinase activity, GW788388 disrupts TGF-β signaling, leading to the downregulation of Lumican. This compound provides a specific means to modulate Lumican levels by directly interfering with the key receptor involved in the TGF-β pathway, emphasizing its potential therapeutic applications in conditions where Lumican dysregulation contributes to pathogenesis. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947 inhibits Lumican expression by selectively targeting the TGF-β type I receptor (ALK5). As an ATP-competitive inhibitor, LY364947 interferes with ALK5 kinase activity, disrupting downstream TGF-β signaling and leading to the inhibition of Lumican. | ||||||